Implicity Raises €35M for AI Cardiac Monitoring Growth

Paris-based Implicity, a pioneer in AI-driven remote cardiac monitoring, has successfully closed a substantial €35 million funding round. This capital infusion is earmarked for aggressive international expansion, with a strategic focus on penetrating the United States market. The company also plans to enhance its artificial intelligence capabilities, particularly in developing advanced algorithms for predicting heart failure.

The significant investment was spearheaded by European growth capital firm IRIS, with active participation from Five Arrows, the alternative assets division of Rothschild & Co. This backing underscores investor confidence in Implicity's mission to transform cardiology by leveraging technology to improve patient outcomes and streamline clinical workflows.

Dr. Arnaud Rosier, electrophysiologist and co-founder of Implicity, articulated the company's core motivation: "I didn’t become a physician to manage data – I became one to treat patients." He further emphasized the funding's role in enabling scalable patient care, stating, "This funding lets us care for patients at scale, catching the information through the noise to provide the best possible care – and that’s the future of cardiology I’ve been chasing since my first year as an electrophysiologist."

Implicity's achievement arrives amidst a robust investment climate for HealthTech, particularly in remote patient monitoring and AI-enabled medical devices. In 2026 alone, European companies in related fields have collectively attracted approximately €209.6 million. Notable examples include Portugal's Hope Care (€6 million), UK's TidalSense (€16.6 million), and Switzerland's Xsensio (€6 million). France has also seen significant activity, with DentalMonitoring raising €84 million and FineHeart securing €83 million for its heart failure technology.

Nicolas Herschtel, Partner at IRIS' Growth team, highlighted Implicity's unique value proposition: "In the evolving HealthTech landscape, long-term success requires a rare combination of robust technology, strict regulatory clearance, and undeniable clinical utility. Implicity has proven to be a highly trusted partner to complex health systems because its platform directly addresses the administrative and operational crisis facing hospital workforces today." He added, "We are thrilled to back the team as they cement their leadership in the US market and drive the next phase of digital healthcare infrastructure."

Founded in 2016, Implicity operates an independent, universal platform designed to monitor patients with cardiac implantable electronic devices (CIEDs) and heart failure. The company's technology has demonstrated impressive clinical results, including a 26% reduction in mortality and a 4% decrease in hospitalizations. These outcomes have driven adoption across over 250 medical centers, monitoring more than 120,000 patients. Implicity's platform is utilized in major French hospital networks such as AP-HP, CHU Tours, and CHU Grenoble, and at Institut Mutualiste Montsouris, where it facilitated a twentyfold increase in patient monitoring capacity.

François-Xavier Lehman, Director at Five Arrows, commented on the company's impact: "Implicity is a rare company where clinical superiority, regulatory credibility and genuine patient impact come together at scale. By turning fragmented cardiac data into action, it improves outcomes for patients while relieving the operational pressure on hospital teams." The company's focus on aggregating and analyzing data from diverse device manufacturers addresses the critical challenge of data overload faced by clinicians, enabling more efficient and effective patient care.